Primary Liver Cancer (PLC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Primary Liver Cancer (PLC) Market Outlook

Thelansis’s “Primary Liver Cancer (PLC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Primary Liver Cancer (PLC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Primary Liver Cancer (PLC) Overview

Primary liver cancer (PLC) is a malignant disease with significant histological and biological diversity. The clinical manifestations of liver cancer are often nonspecific and not evident until cancer has progressed to an advanced stage. These symptoms may comprise unexplained weight loss, loss of appetite, postprandial fullness, nausea, vomiting, abdominal pain or swelling, jaundice (yellowing of the skin and sclera), pruritus (itchy skin), and fatigue. Primary liver cancer is mainly divided into hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), and HCC-ICC according to pathological type. Each subtype exhibits a distinct genetic makeup and molecular patterns. HCCs are associated with genetic alterations in specific chromosomal regions and genes, including TERT promoter mutation, TP53 deletion, and activation of WNT signaling (CTNNB1 and AXIN1). ICCs exhibit a unique mutational landscape with recurrent mutations, including genetic alterations in TP53, KRAS, isocitrate dehydrogenase (IDH) 1/2, and fibroblast growth factor receptor (FGFR) gene fusions. Combined cHCC-ICCs show ICC-like features, while mixed cHCC-ICCs exhibit HCC-like features. The prognosis of liver cancer is affected by many factors, including tumor factors, the patient’s general state of health, and liver function. Therefore, several staging systems exist, such as the BCLC, TNM, JSH, and APASL staging systems.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Primary Liver Cancer (PLC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034